"Stable" vs. "silent progressive multiple sclerosis": a real-world retrospective clinical imaging Brazilian study.
Arq Neuropsiquiatr
; 80(4): 405-409, 2022 04.
Article
em En
| MEDLINE
| ID: mdl-35195220
ABSTRACT
BACKGROUND:
Clinical and imaging are required to characterize activity and progression in MS. The parameters for activity are well defined but not those for progression. The ideal aim for long-term treatment is that neither clinical nor imaging signs of disease should be present, and also no brain atrophy.OBJECTIVES:
To conduct a comparative clinical-imaging study focusing on MRI brain volumetry.METHODS:
174 consecutive relapsing-remitting MS patients (McDonald 2001) were studied, focusing on activity and progression. Annual clinical evaluations (relapse rate and EDSS) and MRI data, along with the annualized evolution of the corpus callosum index (CCI), were compared.RESULTS:
Out of 174 patients, 148 were considered clinically "stable" based on EDSS. However, 33 (22.2%) out of this group showed annualized reductions in CCI of more than 0.5%, which was the cutoff for defining significant brain atrophy.CONCLUSIONS:
Among apparently "stable" relapsing-remitting MS patients, 1/5 showed significant brain atrophy over a follow-up period of at least 7 years. We consider it reasonable to suggest that MRI volume sequences should be included in follow-up protocols, so as to provide information on the real treatment response status.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Recidivante-Remitente
/
Esclerose Múltipla
Tipo de estudo:
Guideline
/
Observational_studies
Limite:
Humans
País como assunto:
America do sul
/
Brasil
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article